Apoptotic mechanisms in T47D and MCF-7 human breast cancer cells

LM Mooney1, KA Al-Sakkaf1,2, BL Brown2 and PRM Dobson*,1,2

1Institute for Cancer Studies, Division of Genomic Medicine, Medical School, University of Sheffield, Sheffield S10 2RX, UK; 2Academic Unit of Endocrinology, Division of Genomic Medicine, Medical School, University of Sheffield, Sheffield S10 2RX, UK

To investigate the mechanisms underlying apoptosis in breast cancer cells, staurosporine was used as an apoptotic stimulus in the human breast cancer cell lines MCF-7 and T47D. Staurosporine induced dose and time dependent increases in DNA fragmentation which was abrogated by z-VAD-fmk. MCF-7 cells did not express caspase-3, suggesting that DNA fragmentation occurred in the absence of caspase-3 and that other caspases may be involved. Staurosporine induced DEVDase activity in T47D cells suggesting the involvement of caspase-3 and/or caspase-7, yet there was no DEVDase activity in MCF-7 cells, probably ruling out the involvement caspase-7. However, staurosporine induced the cleavage of pro-caspase-6 in MCF-7 cells, but not in T47D cells. Caspase dependent PARP cleavage was detected in MCF-7 cells at 3 h, whereas only partial PARP cleavage was detected in T47D cells and then only after 24 h. Moreover, staurosporine led to cytochrome c release at 2 h in MCF-7 cells and 6 h in T47D cells. In addition, a time dependent and caspase-independent reduction of the mitochondrial transmembrane potential was observed; which appeared to occur after the release of cytochrome c. Translocation of Bax from the cytosol to mitochondria was observed in both cell types, and this preceded cytochrome c release in both T47D and MCF-7 cells. Apoptotic events in both cell types differ temporally, involving activation of different caspases and mitochondrial changes.

Keywords: apoptosis; breast cancer; caspase-3; staurosporine

Apoptosis is an essential process in both multi-cellular development, and in maintaining cellular homeostasis. Moreover, failure of damaged cells to undergo apoptosis contributes to the progression of cancer as it allows the persistence of DNA damaged cells. It is therefore of interest to understand apoptotic signalling pathways in different cancer types. Apoptosis is morphologically defined by cell shrinkage, membrane blebbing, chromatin condensation and formation of apoptotic bodies. Central to the apoptotic process is a family of cysteine proteases termed caspases which are crucial effectors of this cell death process. Caspases exist in the cell as inactive pro-enzymes that can be activated either by auto-catalytic processing or by being activated by another caspase (Earnshaw et al, 1999). These proteases can be classified into two groups: ‘initiator’ caspases e.g. caspases-8 and -9, which have long prodomains at the NH2-termini and have the ability to be self-cleaved on oligomerisation, and ‘effector’ caspases e.g. caspases-3, -6 and -7 that have short prodomains and can be activated by initiator caspases or by activated effector caspases (Thornberry and Lazebnik, 1998). Once activated by apoptotic stimuli, caspases contribute to the morphological and biochemical changes of apoptosis by catalysing the proteolysis and disabling of numerous key structural and regulatory proteins within the cell such as, poly-ADP-ribose polymerase (PARP), gelsolin, cytokeratins and DNA fragmentation factor 45 kDa (DFF45) (Nunez et al, 1998).

The Bcl-2 family of anti- (Bcl-2, Bcl-xL, Mcl-1) and pro-apoptotic (Bax, Bad, Bid) proteins are also important in the regulation of cell death. Bcl-2 family members have the ability to form homo- and hetero-dimers and the ratio of anti- and pro-apoptotic proteins may determine the fate of the cell (Reed, 1998). These proteins can be either membrane bound or cytosolic. Bcl-2 has been shown to be localised to the endoplasmic reticulum, mitochondrial membrane and the nuclear envelope (Krajewski et al, 1993), whereas other members such as Bax and Bid are mainly cytosolic. However on induction of apoptosis, localisation of some Bcl-2 family members alters. For example, Bax has been shown to translocate from the cytosol to the mitochondrial membrane after treatment with an apoptotic stimulus (Zhang et al, 1998), and cause subsequent cytochrome c release and caspase activation. Due to their diversity in function these proteins constitute an important point of regulation in the apoptotic pathway.

An alteration in mitochondrial function has been demonstrated to play a key role in the effector phase of the apoptotic pathway. A reduction in the mitochondrial transmembrane potential (ΔΨm) and release of the mitochondrial protein cytochrome c is often observed during apoptosis (Zamzami et al, 1995; Liu et al, 1996). On induction of apoptosis cytochrome c is released from the intermembrane space into the cytoplasm where it leads to activation of caspases and subsequent cell death (Liu et al, 1996). Mitochondrial transmembrane potential breakdown is thought to be mediated by the opening of a large conductance channel known as the mitochondrial permeability transition pore (PTP) (Zamzami et al, 1996). Studies have shown cytochrome c release to occur in the absence of, or to precede ΔΨm disruption (Bossy-Wetzel et al,
Experimental Therapeutics

910

7C

were pooled and were fixed in 1% paraformaldehyde and permea-

presence or absence of z-VAD-fmk. Adherent and detached cells

The order of apoptotic events appears to vary widely depending

on the cellular background and the apoptotic stimulus. It is, there-
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% (v v⁻¹) NP-40, 0.625% sodium deoxycholate, 1 mM NaF, 1 mM Na₂VO₄, 1 protease cocktail tablet (Boehringer Mannheim)). Equal amounts of total protein (30 μg) were subjected to 14% (Bcl-2 family proteins, cytochrome c and cytochrome c oxidase), 8% (Poly ADP-Ribose Polymerase (PARP)) or 10% (caspase-6) SDS–PAGE followed by Western transfer onto a PVDF membrane. Membranes were incubated with antibodies against Bcl-2, Bax, Bak and Bcl-xL, PARP, caspase-6 or cytochrome c and detected with the appropriate species-specific secondary HRP-conjugated antibody. Proteins were detected using the ECL system (Amersham, UK).

RESULTS
Staurosporine induced apoptosis in T47D and MCF-7 human breast cancer cells

Studied of apoptosis, as determined by DNA fragmentation (ISNT), demonstrated that T47D and MCF-7 cells, when exposed to STS (0.2–1 μM), exhibited a concentration-dependent increase in apoptosis, with maximal effects for both cells being at 1 μM STS (data not shown). Apoptosis was also a time-dependent process. When exposed to 1 μM STS, a significant increase in cells displaying DNA fragmentation was evident at 14 h in T47D cells, yet apoptotic changes were detected as early as 4 h in MCF-7 cells (Figure 1A). We further examined DNA fragmentation by cell death ELISA. Results presented in Figure 1B show a time-dependent increase in the presence of mono- and oligo-nucleosomes similar to that observed with ISNT in both cell types, with MCF-7 cells exhibiting greater levels of apoptosis. The apoptotic effect was confirmed by nuclear morphology (Figure 1C), with both cell types showing smaller nuclei and chromatin condensation resulting in the formation of crescent shapes around the periphery of the nucleus. However, T47D cells displayed apoptotic body formation although this was absent from MCF-7 cells (Figure 1C). Furthermore, plasma membrane changes, such as exposure of phosphatidylserine (PS) residues to the outer surface of the plasma membrane were evident during STS-induced apoptosis. STS induced an increase in binding of annexin-V in MCF-7 cells after 4 h of treatment and continued to increase, however this occurred later in T47D cells where significant annexin-V binding was achieved 12 h after 1 μM STS (Figure 2). No changes in annexin-V binding were detected before 12 h in T47D cell (data not shown). This demonstrates that plasma membrane changes probably occur just prior to DNA fragmentation in T47D cells however, in MCF-7 cells these changes appear to occur simultaneously.

DNA fragmentation is mostly mediated by caspase-3 cleavage of the inhibitory protein DFF45 resulting in release of the endonuclease DFF40 which is then free to cleave DNA (Enari et al, 1998; Wolf et al, 1999). It has been shown that MCF-7 cells lack caspase-3 protein. Caspase-3 expression was also absent in the MCF-7 cells used in this study, however we detected caspase-3 expression in T47D cells (data not shown). Therefore in contrast recent studies where lack of DNA fragmentation in response to TNFα and STS was reported (Janicke et al, 1998b), these results (Figure 3A) show that despite the absence of caspase-3, DNA fragmentation was detectable in MCF-7 cells.

Caspase involvement in staurosporine induced apoptosis of T47D and MCF-7 breast cancer cells

To examine whether caspases were involved in STS induced apoptosis, cells were pre-incubated for 1 h with z-VAD-fmk, a broad spectrum caspase inhibitor and were then treated for 16 h with 1 μM STS. As shown in Figure 3, z-VAD-fmk abrogated the apoptotic effect of STS in both T47D and MCF-7 cells. This demonstrates that STS-induced apoptosis requires activation of the caspase family of proteases. We then examined the activity of effector caspases firstly using the substrate DEVD which is the recognition site for caspases-3 and -7. There was no significant increase in DEVDase activity in MCF-7 cells at 12 and 24 h of treatment implying lack of involvement of caspase-7 since these cells do not express caspase-3 (Figure 3B). However, in T47D cells a time-dependent increase in DEVDase was observed from 12 h of treatment, which reachs maximal levels at 48 h implying involvement of caspase-3 and/or -7 in these cells (Figure 3B).

Effector caspase-6 was analysed by assessing disappearance of the full length protein by Western blotting. Levels of pro-caspase-6 protein did not alter in response to STS in T47D cells (Figure 3C). In contrast, in MCF-7 cells, pro-caspase-6 levels decreased following treatment with STS at 16 and 24 h (Figure 3C). Therefore, STS, appeared to induce a time dependent increase in caspase-3 or -7 activity in T47D cells and activation of caspase-6 in MCF-7 cells.

Activation of the caspase cascade leads to cleavage of cellular proteins such as the DNA repair enzyme poly-ADP-ribos polymerase (PARP); cleavage results in inactivation of the enzyme. STS induced PARP cleavage in a time-dependent manner in MCF-7 cells; the 85 kDa cleavage product was observed as early as 3 h after treatment and this increased dramatically by 16 h (Figure 4A). PARP cleavage was abrogated on pre-treatment with z-VAD-fmk (Figure 4A). However, in T47D cells PARP cleavage was not detectable until 24 and 48 h of treatment, however only partial cleavage was evident; the level of full length protein 48 h after treatment was similar to that of control cells (Figure 4B). PARP cleavage was also inhibited by z-VAD-fmk in T47D cells.

Staurosporine induces a reduction in the mitochondrial transmembrane potential (ΔΨm) and release of cytochrome c in T47D and MCF-7 human breast cancer cells

Alterations in the mitochondrial transmembrane potential (ΔΨm) have been shown to be important for the release of mitochondrial proteins such as cytochrome c, which when in the cytosol can lead to activation of the caspase cascade and subsequent death (Reed, 1997). We measured the mitochondrial transmembrane potential (ΔΨm) by staining with 40 μM DiOC₆(3) after treatment with 1 μM STS. STS caused a time-dependent reduction in the mitochondrial transmembrane potential (ΔΨm) in MCF-7 and T47D cells (Figure 5A). In MCF-7 cells this was significant 3 h after treatment whereas significant changes were not observed until 8 h in T47D cells (Figure 5A). At each time point the majority of cells were PI negative implying this mitochondrial alteration occurs before any membrane changes. Moreover, Mitotracker Red staining at these time points was low and diffuse (data not shown), substantiating a reduction in ΔΨm after STS treatment. To verify that the breakdown of ΔΨm is an early event during STS induced apoptosis and was not subsequent to caspase activation, we tested the effect of z-VAD-fmk on the loss of ΔΨm. Cells were pre-incubated with z-VAD-fmk and then treated with 1 μM STS for 6 h. As shown in Figure 6B, z-VAD-fmk had no effect on the reduction in ΔΨm at 6 h in either T47D or MCF-7 cells, suggesting this effect to be caspase-independent. To determine the effect of STS on cytochrome c release, cytotoxic extracts were assessed by Western blotting. The results show that cytochrome c release was observed at 2 h after STS treatment in MCF-7 cells and 4 h after treatment in T47D cells (Figure 6A,B). Cytochrome c oxidase subunit II was used as a mitochondrial marker. Cytochrome c oxidase was not detected in any cytotoxic extracts (Figure 6A,B) demonstrating no mitochondrial contamination. The data suggest that mitochondrial dependent mechanisms contribute to STS mediated apoptosis in
breast cancer cells and that these events occur very early in the apoptotic pathway.

Effect of Staurosporine on Bcl-2, Bcl-xL Bak and Bax protein expression and Bax localisation in human breast cancer cells

There are numerous studies suggesting that overexpression of Bcl-2 or Bcl-xL can block apoptosis by effects at the mitochondrion (Shimizu et al., 1996; Susin et al., 1997; Yang et al., 1997), whereas Bak and Bax have been shown to exert pro-apoptotic activity (Chittenden et al., 1995; Narita et al., 1998). We examined the effect of STS on the expression levels of Bcl-2, Bcl-xL, Bak and Bax proteins. In MCF-7 and T47D cells STS did not alter Bcl-2, Bcl-xL, Bak nor Bak protein expression from 3 to 24 h (MCF-7 cells) or 6 to 48 h (T47D cells) of treatment (data not shown). Bcl-2 expression in T47D cells was not detected by Western blotting, which is in agreement with a previous report (Zapata et al., 1998). Therefore STS mediated apoptosis in T47D and MCF-7 cells does not involve alterations in the expression of Bcl-2, Bcl-xL, Bak or Bax proteins.

Bax translocation from the cytosol to the mitochondria has been demonstrated to occur in many cell lines in response to a variety of apoptotic inducers (Hsu et al., 1997; Gross et al., 1998). In order to determine the localisation of Bax in MCF-7 and T47D cells we exposed cells to 1 μM STS then prepared cytosolic fractions. As shown in Figure 7, Bax protein levels decrease with time in the cytosolic extracts of MCF-7 and T47D cells, 3 and 8 h after treatment respectively. This is consistent with Bax translocating to the mitochondria after treatment with STS and that this occurs following the release of cytochrome c in both cell types, and also that this redistribution is an early event in these cells preceding PARP cleavage and caspase activation.

DISCUSSION

Many chemotherapeutic drugs have been shown to induce apoptosis in various cancer types. It is therefore important to understand

Figure 1  Staurosporine induced apoptosis in T47D and MCF-7 human breast cancer cells. (A) Cells were treated with 1 μM STS for the times indicated and apoptosis was determined by DNA fragmentation (ISNT) on fixed and permeabilised cells. Data are presented as per cent DNA fragmentation: error bars represent the mean ± s.e.m. of three independent experiments. (B) Cells were treated with 1 μM STS for the times indicated, lysates were analysed by ELISA according to the manufacturer's instructions. Fold induction in apoptosis is expressed as amount of cytoplasm DNA-histone complexes in treated cells compared to untreated controls. Error bars represent the mean ± s.e.m. of three independent experiments where * indicates statistically significant increase in apoptosis compared to untreated control (0 h), (ANOVA: F=5.44, P<0.05, df 2.9, Tukey multiple comparison test, P<0.05). (C) Apoptotic nuclear morphology. (i) T47D cells (ii) MCF-7 cells. Cells were treated with 1 μM STS for 16 h, then washed in PBS, fixed, permeabilised and stained with 1 μg ml⁻¹ DAPI. Cells were then analysed by fluorescent microscopy.
Figure 2  Staurosporine induced a time dependent increase in annexin-V binding in (A) T47D and (B) MCF-7 cells. Both T47D and MCF-7 cells were treated with 1 μM STS for the times indicated. Cells were washed in PBS and stained with annexin-V-FITC and PI and analysed by Flow Cytometry. Cells staining annexin-V-FITC+/PI- were considered apoptotic; cells staining annexin-V-FITC+/PI+ were classified as late apoptotic/necrotic. Data are presented as per cent of cells in each classification. Error bars represent the mean ± s.e.m. of three independent experiments.

Figure 3  Staurosporine induced apoptosis activation of the caspase cascade in both MCF-7 and T47D cells. (A) Cells were pre-incubated with 100 μM z-VAD-fmk (Z-VAD) for 1 h prior to the addition of 1 μM STS for 16 h. Cells were fixed, permeabilised and DNA fragmentation detected by ISNT. Error bars represent the mean ± s.e.m. of four independent experiments. (B) Cells were treated for different time periods with 1 μM STS. Cell lysates were prepared and incubated with Ac-DEVD-pNA (caspase-3/7). The reaction products were measured at 405 nm after a 4 h incubation. Error bars represent the mean ± s.e.m. of four independent experiments where * indicates statistically significant increase in DEVDase activity compared to untreated control (0 h), (ANOVA: F=3.38, P<0.05, d.f 3,12. Tukey multiple comparison test, P<0.05). (C) Full length caspase-6 protein is cleaved in MCF-7 but not in T47D cells after treatment. Cells were treated with 1 μM STS for indicated times, lysates prepared and 50 μg protein subjected to SDS–PAGE followed by Western transfer and probed with caspase-6 antibody. C indicates untreated cells. The results are representative of three independent experiments.
Figure 4 Staurosporine induced PARP cleavage in MCF-7 and T47D cells. Both (A) MCF-7 and (B) T47D cells were either treated with 1 μM STS for the times indicated or pre-incubated with 100 μM z-VAD-fmk for 1 h prior to STS treatments. Cell lysates (40 μg protein) were prepared and samples subjected to 8% SDS–PAGE followed by Western transfer and probed with PARP antibody (full length protein is 113 kDa, and cleaved fragment is 85 kDa). The results are representative of three independent experiments.

how each drug acts to induce apoptosis on certain cancers. Staurosporine has been shown to induce apoptosis in many cell types including, cardiomyocytes (Yue et al, 1997), chang liver cells (Swe and Sit, 1997), fibroblasts (Jacobson et al, 1996) and Jurkat T cells (Takahashi et al, 1997). Here we studied its effect and mechanisms of action on breast cancer cells. T47D and MCF-7 cells both underwent apoptosis in response to STS. MCF-7 cells were more sensitive to STS than T47D cells, and the onset of apoptotic events was different, with MCF-7 cells appearing to respond to STS induced apoptosis earlier. Maximal apoptosis was achieved 24 h after exposure to 1 μM STS in MCF-7 cells whereas this was 48 h in T47D cells. DNA fragmentation is an endpoint characteristic of apoptosis occurring after caspase activation. DFF45 is an inhibitor of an endonuclease DFF40. Once DFF45 is cleaved by caspasess, DFF40 is then active and free to cause DNA fragmentation. Recent studies have suggested that caspase-3 and -7 and no other caspase so far identified are essential to cleave DFF45 and result in active DFF40 (Liu et al, 1999), and that caspase-3 was essential for DNA fragmentation in MCF-7 cells (Tang and Kidd, 1998; Zapata et al, 1998). However, as the MCF-7 cells used in the present study did not express caspase-3 protein, the possibility existed that caspase-7 might substitute for caspase-3. Indeed, our results show DNA fragmentation in both cell types was completely inhibited by z-VAD-fmk implying this effect to be caspase mediated. However, DEV-Dase activity was not detected in MCF-7 cells in response to STS suggesting that caspase-7 is not involved. Therefore, we suggest that in MCF-7 cells another mechanism exists, which is a caspase-3 independent pathway causing the DNA fragmentation observed in this study. Many studies have utilised MCF-7 cells to study apoptosis and have demonstrated DNA fragmentation in response to many stimuli (Saunders et al, 1997; Hishikawa et al, 1999; Tudor et al, 2000). For example, nitric oxide induced apoptosis in MCF-7 cells with a lack of DEV-Dase activity substantiating the suggestion for an alternative mechanism in MCF-7 and possibly other cells that do not express caspase-3 (Umansky et al, 2000). More recently it has been demonstrated that in the absence of caspase-3 in MCF-7 cells, DNA fragmentation did not occur and cytochrome c release was slower compared to caspase-3 expressing cells (Blanc et al, 2000). Also caspase-9 processing was impaired in response to cisplatin in MCF-7 cells. Such different findings to our results could be due to the difference in the variants of MCF-7 cells used. There have been many studies highlighting the differences in MCF-7 cell variants (Osborne et al, 1987; Burow et al, 1998; Gooch and Yee, 1999) by illustrating the differences in DNA fragmentation in response to a variety of apoptotic stimuli. Yet it is clear that, in the absence of caspase-3, MCF-7 cells do undergo caspase-3 independent DNA fragmentation. Indeed, caspase-3 $\rightarrow$ I/O hepatocytes and thymocytes do display DNA fragmentation although, with delayed kinetics compared to caspase-3 $\rightarrow$/+ cells (Zheng et al, 1998). This also points to an alternative mechanism independent of DFF45/DFF40 in caspase-3 deficient cells. In this study, DNA fragmentation was inhibited by z-VAD-fmk implying that another caspase is involved. Recent cloning of DFF45/ICAD homologues (Inohara et al, 1998) raise the possibility that other DFF45/DFF40 complexes exist which can be activated independently of caspase-3. Indeed, in support of this idea it has been demonstrated that, in the absence of caspase-3, hepatocyte cells induce compensatory caspase activation, such as caspase-6 (Zheng et al, 2000). This could also be the case for MCF-7 cells, as we have shown that...
Results are representative of three independent experiments.

caspase-6 is activated in the absence of caspase-3 and may therefore illustrate redundancy within the caspase family of proteases. Although caspase-6 processing was detected in MCF-7 cells, full length protein was still present at 24 h. Caspase-6 processing has been shown to require caspase-9 and caspase-3; therefore in the absence of caspase-3 this could explain why partial processing was observed. In T47D cells, DEVDase activity was detected implying the classical pathway leading to cleavage of DFF45 and subsequent DNA fragmentation occurs. In addition, T47D cells displayed typical apoptotic morphology yet in MCF-7 cells apoptotic body formation was absent. Apoptotic body formation involves p21 activated kinase (PAK2) which when cleaved becomes constitutively active and has been demonstrated to be a substrate of caspase-3 (Rudel and Bokoch, 1997). In the absence of caspase-3, PAK2 would not be activated and this could account for the abnormal apoptotic morphology in MCF-7 cells. Proteolytic processing of PARP was detected at 3 h in MCF-7 cells yet changes in caspase-6 were not observed until 16 h. However, release of cytochrome c into the cytoplasm leads to the formation of an apoptosome, which is a complex of dATP, cytochrome c, Apaf-1 and procaspase-9 that results in activation of caspase-9. PARP is also a substrate for caspase-9 therefore the activation of caspase-9, could account for the early cleavage of PARP in MCF-7 cells. In T47D cells only partial PARP cleavage was observed at 24 and 48 h of treatment which was coincident with DEVDase activity.

Mitochondrial changes were observed in both MCF-7 and T47D cells but again with different kinetics. We have demonstrated cytochrome c release from the mitochondria to the cytosol in both MCF-7 and T47D cells at 2 and 4 h respectively. Cytochrome c release from mitochondria that occurs after STS treatment is possibly controlled by Bax. Bax has been shown to be cytosolic and in association with intracellular membranes including the mitochondrial membrane, but upon apoptotic stimuli Bax inserts into the mitochondrial membrane and leads to the release of cytochrome c (Goping et al, 1998). It has also been shown that Bax redistribution occurs in cells at different times (Wolter et al, 1997). In MCF-7 and T47D cells, Bax protein levels declined in the cytosol at 3 and 8 h respectively after treatment, which was subsequent to cytochrome c release. It is therefore possible that, in these cells, sufficient Bax resides at the mitochondrial membrane to induce cytochrome c release after a death signal, and further apoptotic insult leads to increasing amounts of Bax translocating to the mitochondria. This could explain why we do not observe significant changes in Bax protein translocation until 3 and 8 h after STS exposure, although it does not rule out Bax being responsible for cytochrome c release. In addition to triggering cytochrome c release, Bax induces a reduction in the mitochondrial transmembrane potential (ΔΨm). This was observed at 3 h in MCF-7 cells and 6 h in T47D cells, and occurred coincident with significant Bax translocation. In both cases, the release of cytochrome c into the cytosol preceded the loss of ΔΨm, which is consistent with a caspase independent mechanism upstream of the mitochondria. Loss of ΔΨm has been postulated to involve opening of a large permeability transition pore (PTP). This would suggest that in

**Figure 6** Staurosporine induced cytochrome c release into the cytosol of (A) MCF-7 and (B) T47D cells. After treatment with 1 μM STS for the times indicated cytosolic extracts were prepared and 30 μg protein subjected to antibody (Cyt c) and cytochrome c oxidase subunit II (Cyt Ox) Western blot analysis with anti-cytochrome c and anti-cytosolic extract. Whole cell lysate (WCL) was used as a positive control for the cytochrome c oxidase. Results are representative of four independent experiments.

**Figure 7** Staurosporine induced Bax redistribution from the cytosol to the mitochondria in breast cancer cells (A) MCF-7 (B) T47D. After incubation with 1 μM STS for the indicated times cytosolic extracts were prepared and subjected to 14% SDS-PAGE followed by Western blot analysis with anti-cytochrome c and anti-Bax or anti cytochrome c oxidase subunit II antibody. Also shown are the Bax levels in the whole cell lysate of (C) MCF-7 and (D) T47D cells respectively. Results are representative of three independent experiments.
MCF-7 and T47D cells cytochrome c release occurs independently of PTP opening.

Taken together, our data demonstrate that the mechanism of STS mediated activation of different caspase cascades in T47D and MCF-7 cells involved the release of cytochrome c, loss of ΔΨm and Bax redistribution. Interestingly, despite the lack of caspase-3, MCF-7 cells proceeded to apoptosis more rapidly. Also, the lag time between the earliest event observed (cytochrome c caspase-3, MCF-7 cells) was longer in T47D cells (around 8 h) than in the caspase-3 deficient MCF-7 cells (around 1–2 h). This study provides further evidence for the existence of another mechanism of DNA fragmentation in the absence of caspase-3. However, we have also shown that two similar tumour types undergo STS induced apoptosis with similar outcomes, but with very different kinetics, and emphasising that pathways to apoptosis can be very different in similar cell types. Such variations may have relevance to tumour progression in a clinical setting since cell may respond differently to chemotherapy, and perhaps also to survival factors.

ACKNOWLEDGEMENTS

We are grateful to the University of Sheffield Cancer Research Fund and to the Yorkshire Cancer Research (YCR) for funding this work. We also thank Dr J Lawry and Mrs Olivia Smith for help with Flow Cytometry.

REFERENCES

Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, Reed JC, Jagger R, Marti A (2000) Caspase 3 is essential for procaspase 9 processing and cisplatin induced apoptosis of MCF-7 breast cancer cells. Cancer Res 60: 4386 – 4390

Bossy-Wetzel E, Newmeyer DD, Green DR (1998) Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J 17: 37 – 49

Burrow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, Hammond TG, Clejan S, Beckman BS (1998) Differences in susceptibility to tumor necrosis factor α-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res 58: 4940 – 4946

Chittenden T, Harrington EA, O’Connor R, Flemington C, Lutz RZ, Evan GI, Guild BC (1995) Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374: 733 – 736

Decaudin D, Geley S, Hirsch T, Castedo M, Macho A, Kofler K, Kroemer G (1997) Bcl-2 and Bcl-xl antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 57: 62 – 67

Earnshaw WC, Martins LM, Kaufmann SH (1999) Mammalian Caspases: Structure, activation, substrates and functions during apoptosis. Ann Rev Biochem 68: 383 – 424

Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S (1998) A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. EMBO J 17: 43 – 50

Goldstein JC, Waterhouse NJ, Juin P, Evan G, Green DR (2000) The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2: 156 – 162

Gooch JL, Yee D (1999) Strain specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. Cancer Lett 144: 31 – 37

Goping IS, Gross A, Lavoie JN, Nguyen M, Jemmerson R, Roth K, Korsmeyer SJ, Shore GC (1998) Regulated targeting of Bax to mitochondria. J Cell Biol 143: 207 – 215

Gross A, Jockel J, Wei MC, Korsmeyer SJ (1998) Enforced dimerisation of Bax results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 17: 3878 – 3888

Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Luscher TF, Fujii T (1999) Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem 274: 37461 – 37466

Hsu Y, Wolfer KG, Youle RJ (1997) Cytosol to membrane redistribution of Bax and Bcl-xl during apoptosis. Proc Natl Acad Sci USA 94: 3668 – 3672

Inohara N, Kosaki T, Chen S, Wu X, Nunez G (1998) CIDE, a novel family of cell death activators with homology to the 45 Kda subunit of the DNA fragmentation factor. EMBO J 17: 2526 – 2533

Jacobson MD, Weil M, Raff MC (1996) Role of Ced-3/ICE family proteases in cisplatin induced apoptosis of MCF-7 breast cancer cells. J Biol Chem 271: 15428 – 15455

Janicke RU, Ng P, Sprengart ML, Porter AG (1998a) Caspase-3 is required for fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 273: 15540 – 15545

Janicke RU, Sprengart ML, Wait MR, Porter AG (1998b) Caspase 3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357 – 9360

Jurgensmeier J, Xie Z, Deveraux Q, Eellerby L, Brodelsen D, Reed JC (1998) Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 95: 4997 – 5002

Krajewski S, Tanaka S, Takayama S, Schibli MJ, Fenton W, Reed JC (1993) Investigation of the subcellular distribution of Bcl-2 onco-protein: Residence in the nuclear envelope, endoplasmic reticulum and outer mitochondrial membranes. Cancer Res 53: 4701 – 4714

Liu X, Kim CN, Yang J, Jemmerson R, Wang X (1996) Induction of apoptotic program in cell free extracts: requirement for dATP and cytochrome c. Cell 86: 147 – 157

Liu X, Zou H, Widalak P, Garrard W, Wang X (1999) Activation of the apoptotic endonuclease DFF40 (Caspase activated Dnase or Nuclease). Oligomerisation and direct interaction with histone H1. J Biol Chem 274: 13836 – 13840

Narita N, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H, Tsujimoto Y (1998) Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci USA 95: 14681 – 14686

Nunez G, Benedict MA, Hu Y, Inohara N (1998) Caspases: the proteases of the apoptotic pathway. Oncogene 17: 3237 – 3245

Osborne CK, Hobbis K, Trent JM (1987) Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast. Cancer Res Treat 9: 111 – 121

Reed JC (1997) Cytochrome c: can’t live with it – can’t live without it. Cell 91: 559 – 562

Reed JC (1998) Bcl-2 family proteins. Oncogene 17: 3225 – 3236

Rudel T, Bokoch GM (1997) Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 276: 1571 – 1574

Saunders DE, Lawrence WD, Christensen G, Wappner NL, Ruan H, Deppe G (1997) Paclitaxel-induced apoptosis in MCF-7 breast cancer cells. Int J Can 70: 214 – 220

Shimizu S, Eguchi Y, Kamiike K, Waguil S, Uchiyama Y, Matsuda S, Tsujimoto Y (1996) Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors. Oncogene 13: 21 – 29

Susin SA, Zamzami N, Castedo M, Duagas E, Wang HG, Gelay S, Fassy F, Reed JC, Kroemer G (1997) The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J Exp Med 186: 25 – 37

Swe M, Sit KH (1997) Staurosporine induces telophase arrest and apoptosis, blocking mitosis exit in humanchang liver cells. Biochem Biophys Res Commun 236: 594 – 598

Takahashi A, Hirata H, Yonehara S, Imai Y, Lee K, Moyer RW, Turner PC, Mesner PW, Okazaki T, Sawai H, Kishi S, Yamamoto K, Okuma M, Sasada M (1997) Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine, and CrmA-sensitive caspase 8. Oncogene 14: 2741 – 2752

Tang D, Kidd VJ (1998) Cleavage of DFF45/ICAD by multiple caspases is essential for its function during apoptosis. J Biol Chem 273: 28549 – 28552

Thornberry NA, Lazebnik Y (1998) Caspases: Enemies within. Science 281: 1312 – 1316

LM Mooney et al

Staurosporine induced apoptosis in breast cancer cells

British Journal of Cancer (2002) 87(8), 909 – 917 © 2002 Cancer Research UK
Tudor G, Aguilera A, Halverson DO, Laing ND, Sausville EA (2000) Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-x1 protein levels. Cell Death Diff 7: 574–586

Umansky V, Ushmorov A, Ratter F, Chlichlia K, Bucur M, Lichtenauer A, Rocha M (2000) Nitric oxide mediated apoptosis in human breast cancer cells requires changes in mitochondrial functions and is independent of CD95 (APO-1/Fas). Int J Oncol 16: 109–117

Wolf BB, Schuler M, Echeverri F, Green DR (1999) Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/Inhibitor of caspase-activated Dnase inactivation. J Biol Chem 274: 30651–30656

Wolter KG, Hsu Y, Smith CL, Nechushtan A, Xi X, Youle RJ (1997) Movement of bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139: 1281 –1292

Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kagi D, Hakem A, McCurrach M, Khoo W, Kaufman SA, Senaldi G, Howard T, Lowe SW, Mak TW (1998) Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 12: 806–819

Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T, Jones DP, Wang X (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129–1132

Yue T, Wang C, Romanic AM, Kikly K, Keller P, DeWolf Jr WE, Hart TK, Thomas HC, Storer B, Gu J, Wang X, Feuerstein GZ (1998) Staurosporine induced apoptosis in cardiomyocytes: a potential role of caspase-3. J Mol Cell Cardiol 30: 495–507

Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B, Kroemer G (1995) Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 182: 367–377

Zamzami N, Marchetti P, Castedo M, Hirsch T, Susin SA, Masse B, Kroemer G (1996) Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Letts 384: 53–57

Zapata JM, Krajewski M, Krajewski S, Huang R, Takayama S, Wang H, Adamson E, Reed JC (1998) Expression of multiple apoptosis regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat 47: 129–140

Zhang H, Heim J, Meyhack B (1998) Redistribution of Bax from cytosol to membranes is induced by apoptotic stimuli and is an early step in the apoptotic pathway. Biochem Biophys Res Commun 251: 454–459

Zheng TS, Schlosser SF, Dao T, Hingorani R, Crispe IN, Boyer IL, Flavell RA (1998) Caspase 3 controls both cytoplasmic and nuclear events associated with Fas-mediated apoptosis in vivo. Proc Natl Acad Sci USA 95: 13618–13623

Zheng TS, Hunot S, Kuida K, Flavell RA (1999) Caspase knockouts: matters of life and death. Cell Death Diff 6: 1043–1053

Zheng TS, Hunot S, Kuida K, Momoi T, Srinivasan A, Nicholson DW, Lazaebnik Y, Flavell RA (2000) Deficiency in caspase 9 or caspase 3 induces compensatory caspase activation. Nat Med 6: 1241–1247